These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 15162466

  • 1. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J.
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [Abstract] [Full Text] [Related]

  • 2. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO.
    Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
    Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G.
    Transplantation; 2001 Nov 27; 72(10):1675-9. PubMed ID: 11726831
    [Abstract] [Full Text] [Related]

  • 5. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 27; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 6. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr 27; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 7. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
    Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, Lake J.
    Clin Transplant; 2007 Apr 27; 21(4):526-31. PubMed ID: 17645714
    [Abstract] [Full Text] [Related]

  • 8. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
    Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, Muiesan P, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A.
    Transplantation; 2003 Mar 27; 75(6):796-9. PubMed ID: 12660504
    [Abstract] [Full Text] [Related]

  • 9. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    Transplant Proc; 2006 Dec 27; 38(10):3633-5. PubMed ID: 17175352
    [Abstract] [Full Text] [Related]

  • 10. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M.
    Exp Clin Transplant; 2007 Dec 27; 5(2):673-9. PubMed ID: 18194120
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.
    Liver Transpl; 2005 Jan 27; 11(1):61-7. PubMed ID: 15690537
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
    Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, Beckebaum S, Isoniemi H, Pirenne J, Jaray J, MARSILEA Study Group.
    Transplantation; 2008 Dec 27; 86(12):1689-94. PubMed ID: 19104406
    [Abstract] [Full Text] [Related]

  • 16. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
    Orr DW, Portmann BC, Knisely AS, Stoll S, Rela M, Muiesan P, Bowles MJ, Heaton ND, O'Grady JG, Heneghan MA.
    Transplant Proc; 2005 Dec 27; 37(10):4373-9. PubMed ID: 16387124
    [Abstract] [Full Text] [Related]

  • 17. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation.
    Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, Jawan B, Chen CL.
    Liver Transpl; 2005 Oct 27; 11(10):1258-64. PubMed ID: 16184544
    [Abstract] [Full Text] [Related]

  • 18. Initial immunosuppression with or without basiliximab: a comparative study.
    Martín-Mateos RM, Graus J, Albillos A, Arocena C, Rodríguez Gandía MA, Blesa C, García-Hoz F, García González M, García-Alonso FJ, Bárcena R.
    Transplant Proc; 2012 Nov 27; 44(9):2570-2. PubMed ID: 23146457
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.
    Jain A, Sharma R, Ryan C, Tsoulfas G, Orloff M, Abt P, Kashyap R, Batzold P, Sauberman L, Safadjou S, Graham M, Bozorgzadeh A.
    Liver Transpl; 2008 Feb 27; 14(2):202-9. PubMed ID: 18236395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.